Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 178

1.

Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis.

van Halm VP, van Denderen JC, Peters MJ, Twisk JW, van der Paardt M, van der Horst-Bruinsma IE, van de Stadt RJ, de Koning MH, Dijkmans BA, Nurmohamed MT.

Ann Rheum Dis. 2006 Nov;65(11):1473-7. Epub 2006 Apr 27.

2.

Effects of 14 weeks of TNF alpha blockade treatment on lipid profile in ankylosing spondylitis.

Mathieu S, Dubost JJ, Tournadre A, Malochet-Guinamand S, Ristori JM, Soubrier M.

Joint Bone Spine. 2010 Jan;77(1):50-2. doi: 10.1016/j.jbspin.2009.05.012. Epub 2009 Dec 22.

PMID:
20022785
3.

Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis.

van Eijk IC, de Vries MK, Levels JH, Peters MJ, Huizer EE, Dijkmans BA, van der Horst-Bruinsma IE, Hazenberg BP, van de Stadt RJ, Wolbink GJ, Nurmohamed MT.

Arthritis Rheum. 2009 May;60(5):1324-30. doi: 10.1002/art.24492.

4.

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.

Gorman JD, Sack KE, Davis JC Jr.

N Engl J Med. 2002 May 2;346(18):1349-56.

5.

Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis.

Kiortsis DN, Mavridis AK, Filippatos TD, Vasakos S, Nikas SN, Drosos AA.

J Rheumatol. 2006 May;33(5):921-3. Epub 2006 Mar 15.

PMID:
16541480
6.

Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.

Braun J, McHugh N, Singh A, Wajdula JS, Sato R.

Rheumatology (Oxford). 2007 Jun;46(6):999-1004. Epub 2007 Mar 27.

PMID:
17389658
7.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

8.

The Ankylosing Spondylitis Disease Activity Score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-α inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China.

Xu M, Lin Z, Deng X, Li L, Wei Y, Liao Z, Li Q, Wei Q, Hu Z, Zhang Y, Lin Q, Huang J, Li T, Pan Y, Wu Y, Jin O, Yu B, Gu J.

Rheumatology (Oxford). 2011 Aug;50(8):1466-72. doi: 10.1093/rheumatology/ker087. Epub 2011 Mar 26.

PMID:
21441550
9.

The effect of anti-TNF agent on oxidation status in patients with ankylosing spondylitis.

Karkucak M, Capkin E, Alver A, Akyuz A, Kiris A, Ak E, Topbas M, Tosun M.

Clin Rheumatol. 2010 Mar;29(3):303-7. doi: 10.1007/s10067-009-1325-6. Epub 2009 Dec 11.

PMID:
20012550
10.

Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.

Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J.

Arthritis Rheum. 2003 Jun;48(6):1667-75.

11.

No significant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment for 6 and 12 months.

Mathieu S, Pereira B, Couderc M, Rabois E, Dubost JJ, Soubrier M.

Rheumatology (Oxford). 2013 Jan;52(1):204-9. doi: 10.1093/rheumatology/kes272. Epub 2012 Oct 13.

PMID:
23065359
12.

Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab.

Spanakis E, Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G, Karvounaris S, Bizaki A, Kritikos H, Boumpas DT.

J Rheumatol. 2006 Dec;33(12):2440-6. Epub 2006 Oct 1.

PMID:
17014005
13.

Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.

de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans BA, Hazenberg BP, Wolbink GJ.

Arthritis Rheum. 2009 Nov 15;61(11):1484-90. doi: 10.1002/art.24838.

14.

Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.

van der Heijde D, Da Silva JC, Dougados M, Geher P, van der Horst-Bruinsma I, Juanola X, Olivieri I, Raeman F, Settas L, Sieper J, Szechinski J, Walker D, Boussuge MP, Wajdula JS, Paolozzi L, Fatenejad S; Etanercept Study 314 Investigators..

Ann Rheum Dis. 2006 Dec;65(12):1572-7. Epub 2006 Sep 12.

15.

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.

Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W; Enbrel Ankylosing Spondylitis Study Group..

Arthritis Rheum. 2003 Nov;48(11):3230-6.

16.

Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept.

Woo JH, Lee HJ, Sung IH, Kim TH.

J Rheumatol. 2007 Aug;34(8):1753-9. Epub 2007 Jun 15.

PMID:
17610317
17.

[Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].

Yang CH, Huang F, Deng XH, Zhang JL, Zhang LY, Guo JH, Liang DF, Wang LS, Zhang YM.

Zhonghua Yi Xue Za Zhi. 2006 Sep 19;86(35):2451-4. Chinese.

PMID:
17156669
18.

[Clinical study of etanercept for treating ankylosing spondylitis].

Liang LQ, Zhan ZP, Ye YJ, Fu D, Xu HS, Yang XY.

Nan Fang Yi Ke Da Xue Xue Bao. 2008 Aug;28(8):1349-51. Chinese.

19.

Effects of etanercept treatment on lipid profile in patients with moderate-to-severe chronic plaque psoriasis: a retrospective cohort study.

Lestre S, Diamantino F, Veloso L, Fidalgo A, Ferreira A.

Eur J Dermatol. 2011 Nov-Dec;21(6):916-20. doi: 10.1684/ejd.2011.1548.

PMID:
21983007
20.

Associations between inflammation, nocturnal back pain and fatigue in ankylosing spondylitis and improvements with etanercept therapy.

Hammoudeh M, Zack DJ, Li W, Stewart VM, Koenig AS.

J Int Med Res. 2013 Aug;41(4):1150-9. doi: 10.1177/0300060513488501. Epub 2013 Jun 26.

PMID:
23803306

Supplemental Content

Support Center